Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

443
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
443
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

390
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
390
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

256
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
256
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

155
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
155
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

243
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
243
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

467
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
467

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.

Journal of Crohn's & colitis·2026
Same author

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.

Journal of Crohn's & colitis·2026
Same author

Zeitschrift fur Gastroenterologie·2026
Same author

[Updated S3 guideline on ulcerative colitis].

Zeitschrift fur Gastroenterologie·2026
Same author

[Version 7.0 of the S3 Guideline on Ulcerative Colitis sets out clearly defined treatment goals, an open treatment sequence, and a call for improved cross-sectoral care].

Zeitschrift fur Gastroenterologie·2026
Same author

Early transmural response assessed by intestinal ultrasound predicts long-term clinical remission in patients with IBD: Results from the TRUST BEYOND study.

Inflammatory bowel diseases·2026

Related Experiment Video

Updated: Oct 3, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

384

[Living guideline on ulcerative colitis].

Torsten Kucharzik1

  • 1Klinik für Allgemeine Innere Medizin und Gastroenterologie, Klinikum Lüneburg, Bögelstr. 1, 21339, Lüneburg, Deutschland. torsten.kucharzik@klinikum-lueneburg.de.

Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|February 15, 2022
PubMed
Summary

Ulcerative colitis treatment has expanded, with mesalazine for mild cases and advanced therapies like biologics and JAK inhibitors for severe or refractory disease. Surgery is reserved for treatment-resistant cases or cancer.

Keywords:
BiologicalsGlucocorticoidsMesalizineProctocolectomySide effects

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.1K

Related Experiment Videos

Last Updated: Oct 3, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

384
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.1K

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • The therapeutic landscape for ulcerative colitis (UC) has significantly evolved.
  • Mesalazine remains a cornerstone for managing uncomplicated UC.
  • Glucocorticoids offer acute efficacy but are limited by side effects.

Purpose of the Study:

  • To review the current and emerging treatment options for ulcerative colitis.
  • To outline the stepwise approach to managing UC based on disease severity and response.

Main Methods:

  • Literature review of recent advancements in UC pharmacotherapy.
  • Analysis of treatment guidelines and clinical trial data.
  • Discussion of surgical interventions for refractory UC.

Main Results:

  • A broad spectrum of treatments is now available, ranging from mesalazine to advanced biologics.
  • Immunosuppressants, JAK inhibitors, S1PR agonists, and calcineurin inhibitors are options for refractory disease.
  • Proctocolectomy is indicated for treatment-resistant cases or dysplasia/carcinoma.

Conclusions:

  • Current UC management involves a tiered approach, escalating therapy as needed.
  • Novel agents offer new hope for patients with moderate to severe or refractory disease.
  • Surgical options remain critical for specific indications in UC management.